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INTRODUCTION  
  
 
INTRODUCTION  
In this era of in vitro fertilization and genetically engineered babies, there 
still are certain conceptions which end before they reach the maturity causing 
great physical and mental agony to the parents. Though there are innumerable 
causes to this, immunological causes are important which account for 20-50%. 
(1) 
All of us are products of successful conception and gestation across 
immunological barriers, barriers that should result in the rapid rejection of 
fetus.  Yet the fetus is tolerated and successful enough to keep the population 
ever increasing.  The maternal immune system is able to coordinate the 
dichotomous responsibilities to protect the host from pathogenic 
microorganisms without rejecting the antigenically foreign fetus. 
Pregnancy is a unique immunological state where a natural homoeostasis 
exists between antigenically different tissues. One of the many initial 
hypotheses on the maintenance of fetal allograft was that pregnancy was 
associated with suppression of maternal immune response thereby allowing for 
fetal survival, however maintaining the immunocompetence against pathogenic 
microorganisms and neoplasia. 
 The process of implantation is quite complex and in 90% of pregnancies 
it achieves the right balance of hormones, cytokines and growth factors, 
  
 
causing degradation of the endometrium and proliferation of the trophoblast, 
protecting it at the same time from maternal cell mediated immunity.  Nature 
orchestrates a host of substances in a masterly manner to achieve this goal. 
Autoimmunity is the process by which humoral or cellular response is 
directed against specific components of host and is the result of breakdown of 
host immunoregulatory mechanism to discriminate self and nonself antigens. 
Lupus anticoagulant antibody(LAC) and anticardiolipin antibody 
(ACL)are acquired antibodies directed against phospholipids or their binding 
proteins, characteristically found in patients with autoimmune disorders, and 
considered to be an important marker for pregnancy losses and intrauterine 
fetal demise(2). 
Recently lupus and anticardiolipin antibodies have been recognized as 
having a role in recurrent pregnancy loss, even in women with no clinically 
diagnosed autoimmune disease(3). 
  
The association between anti phospholipid antibodies and recurrent 
pregnancy loss is well established (4).  What is still unclear is the actual 
prevalence of anti phospholipid antibodies in women with unexplained 
recurrent pregnancy loss.    
  
 
 Evaluation for the prevalence of these anti bodies in patients with 
recurrent pregnancy loss can improve the out come in future pregnancy (5). 
 
 
  
 
HISTORY 
Antiphospholipid antibodies were first detected during 1906 in patients 
with false positive serological test for syphilis. In 1952, Conley and Hartman 
were the first to describe an in vitro circulating anticoagulant which occurred 
predominantly in patients with Systemic Lupus Erythematosus.  In 1972, 
Feinstein and Rappaport termed the anticoagulant ‘lupus anticoagulant’.  
A possible association between antiphospholipid antibody and pregnancy 
loss was first suggested in case reports by Nilsson et al in 1975 and by Soulier 
and Boffa in 1980.  Subsequent case series by Lubbe et al, Lockshin et al, 
and Branch et al confirmed this association.  By the mid – 1980s, the clinical 
criteria for the newly named antiphospholipid syndrome (APS) were 
established, and pregnancy loss was included as one of the clinical features of 
the disorder.  Harris in 1987 identified the Antiphospholipid Syndrome 
pregnancy loss criterion as fetal loss.  Since that time, definitions and criteria 
have expanded, with the 1999 clinical and laboratory criteria proposed at the 
international Antiphospholipid Symposium in Sapporo, Japan identifying 
current consensus. 
  
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
  
 
 
 
REVIEW OF LITERATURE  
Recurrent pregnancy losses may be caused by a number of mechanisms.  
They can be broadly divided into those caused due to abnormalities in either 
the pregnancy itself or in the environment.  Abnormalities in the pregnancy are 
mainly chromosomal, while abnormalities in the environment are grouped as 
anatomic, immunologic and hormonal (6). 
Chromosomal abnormalities occur in about 50% of all products of 
conception from first trimester miscarriages, 5% of late pregnancy losses and 
0.5% of live births (Boue et al).  When products of conception from over 200 
miscarriages of women with recurrent pregnancy loss were tested with 
chromosomal analysis, 55% were abnormal.  Of interest, only 35% of women 
experiencing recurrent pregnancy loss after a live birth were chromosomally 
abnormal (7).  Some pregnancy losses associated with abnormal chromosomes 
such as an extra chromosome (trisomy) have been reported to have a high risk 
of a repeating.  However, if such “accidents” explained all of recurrent 
miscarriage, the probability of three or more miscarriages in a row resulting 
from “accidents” would account for 5% or less of the observed incidence of 
losses (8).  
  
 
Anatomical lesions are lesions of uterus which if present would 
mechanically inhibit normal implantation and hence normal embryo and/or 
fetal growth. These include congenital factors (Mullerian duct anomalies) and 
acquired factors (Cervical incompetence, uterine synechiae, sub mucous fibroid 
and polyps) (9). 
Hormonal (Luteal phase) defect was diagnosed by endometrial dating in 
the past.  However the results of endometrial biopsy have failed to correlate 
with pregnancy outcome (10). Poly cystic ovary disease, uncontrolled Diabetes 
mellitus, Thyroid disorders, and hyperprolactinemia may lead to pregnancy 
wastage. 
Immunologic mechanisms have recently been recognized as a major 
cause of recurrent pregnancy loss associated with the loss of chromosomally 
normal pregnancies.  Forty – five percent of miscarriages and 95% of late 
pregnancy losses from women experiencing recurrent pregnancy loss are 
chromosomally normal.  Approximately 75% of chromosomally normal 
preimplantation embryos fail to implant.  A literature is developing which 
suggests a role of the immune system in the majority of these losses (11).  
 
 The end result of the immunologic processes that leads to loss of the 
pregnancy involves interference of the blood supply to the pregnancy.  
  
 
Interference of blood supply among early and late pregnancy losses is 
manifested by clotting of the placental/fetal vessels (12).  Clotting may be 
caused by  
 cytokines that are produced by immunological cells or 
 by antiphospholipid antibodies produced by B cells or  
 by a genetic predisposition contributed by thrombophilia 
gene. 
  ANTIPHOSPHOLIPID ANTIBODIES 
Antiphospholipid antibodies are a class of antibodies directed against 
phospholipids and include anticardiolipin antibody and lupus anticoagulant.  
Their prevalence in a general obstetric population is around 2-7%. In low-risk 
pregnancies, this carries a 3-9 fold risk of fetal loss, but in high – risk 
pregnancies they are associated with a 90% risk of further pregnancy loss (13). 
Lupus anticoagulant antibody is a monoclonal antibody that reacts to the 
phospholipid from blood platelet membrane factor3.  Feinstein and 
Rappaport (1972) introduced the term lupus anticoagulant based on the 
recognition that certain patients with lupus had prolonged coagulation tests and 
suggested some anticoagulant activity.  LAC is associated with a fetal mortality  
  
 
Placental Thrombosis  
  
 
  
 
of 85-92%.  It is present in 2-5% of normal obstetric population, 30% of 
patients with severe preeclampsia and 10% of non – pregnant patients with 
endometriosis (14).  
In patients with recurrent miscarriage, lupus anticoagulant antibody is the 
most common, followed by IgG and IgM anticardiolipin antibodies.  The lupus 
anticoagulant is an inhibitor of the coagulation pathway, and causes 
prolongation of the kaolin clotting time, which is not corrected by mixing the 
patient’s plasma with control plasma. The association between 
antiphospholipid antibodies and thrombosis is stronger for lupus anticoagulant 
and anti beta 2 glycoprotein1   antibodies; the risk of pregnancy loss is related 
to anticardiolipin IgG titers (15).  
PATHOPHYSIOLOGY  
The antiphospholipid antibodies exert their action by binding directly to 
β2glycoprotein1 antibodies as in the case of anticardiolipin antibodies or to 
phospholipid bound prothrombin as in the case of lupus anticoagulant 
antibodies (16). 
β2glycoprotein1 acts by phospholipid dependant anticoagulant inhibition 
of prothrombinase activity and adenosine di phosphate(ADP) induced platelet 
aggregation.  Thus, it specifically inhibits the binding of coagulation factors 
  
 
especially factor XII and prothrombinase to negatively charged phospholipid 
surfaces and prevents activation of coagulation cascade.   
 β2glycoprotein 1 is found in high concentration in syncytiotrophoblast 
and is also involved in implantation; thereby its loss results in either 
intervillous space thrombosis or prevents implantation. 
The proposed mechanisms of pregnancy loss in Antiphospholipid 
antibody syndrome are, 
I. decreased ProstaglandinI2 and increased ThromboxaneA2 
production by endothelial cells. 
II. inhibition of activation of protein C and protein S pathway. 
III. decreased annexin V production, inhibition of its function in 
placenta by antiphospholipid antibody. 
IV. inhibition of heparin dependant activation of antithrombin 
III. 
V. activation of endothelial cells and platelets, increased 
expression of adhesion molecules. 
  
 
Mechanism of Placental Failure 
  
 
PATHOLOGY 
Placenta is one of the major targets of antiphospholipid antibodies.  
Second or third trimester fetal death is widely considered as most specific for 
antiphospholipid syndrome.  First trimester spontaneous abortion is not 
uncommon provided anatomic and chromosomal causes are excluded.   
These are caused by uteroplacental insufficiency, which is attributed to 
vasculopathy involving the terminal branches of the uterine arteries (spiral 
arteries).  This vasculopathy is characterized by absence of normal physiologic 
changes in the myometrial segments of the spiral arteries underlying the 
placenta and accumulation of lipid laden macrophages in the intima, fibrinoid 
necrosis of the media and intimal fibroblastic proliferation.  The worst 
pregnancy outcomes are associated with multifocal uteroplacental thrombosis 
and placental infarction, both extreme expressions of the vasculopathy (5). 
THE CRITERIA FOR THE CLASSIFICATION OF 
ANTIPHOSPHOLIPID SYNDROME (SAPPORO, 1998) was revised in 
2006. 
CLINICAL CRITERIA 
Vascular thrombosis: 
  
 
 One or more episodes of arterial, venous or small vessel thrombosis in 
any organ or tissue, diagnosed objectively. 
Pregnancy morbidity 
 One or more unexplained death of a morphologically 
normal fetus at or beyond 10th week of gestation, 
normality documented by direct examination or 
Ultrasound or 
 One or more premature births of a fetus before 34 weeks 
gestation because of severe preeclampsia or severe 
placental insufficiency or 
 Three or more unexplained consecutive spontaneous 
abortions before the 10th week with maternal anatomic, 
hormonal and paternal karyotype abnormalities excluded. 
LABORATORY CRITERIA 
I. Anticardiolipin antibody of  IgG and / or IgM isotype in 
serum or plasma present in medium or high titer on 2 or 
more occasions at least 12 weeks apart by standardized 
ELISA for β2glycoprotein1 inhibitor dependant ACL 
  
 
II. Lupus anticoagulant present in serum or plasma on 2 or 
more occasions at least 12 weeks apart detected according 
to the gudelines of the International society on 
Thrombosis and Haemostasis. 
III. Anti beta 2 glycoprotein 1 antibody of IgG and / or IgM 
isotype in serum or plasma > 99 percentile present on 2 or 
more occasions atleast 12 weeks apart measured by 
standard ELISA . 
Antiphospholipid antibody syndrome is present when one or more of the 
clinical and one or more of the laboratory criteria are present. 
DIAGNOSIS 
Patients suspected of having antiphospholipid syndrome should be tested 
using at least 2 antiphospholipid antibody assays.  The must commonly 
performed are LAC and ACL.Testing for LAC utilizes in vitro coagulation 
assays include activated Partial Thromboplastin Time, diluted Russell’s viper 
Venom Test, Kaolin Clotting Time, tissue thromboplastin inhibition test.  The 
test for ACL is standardized ELISA.  
LAC tests are reported as positive or negative, ACL as in terms of 
international units of GPL and MPL.  
  
 
 Creagh et al., (1991) investigated 66 women with first or second 
trimester fetal loss for the presence of lupus anticoagulant by routine 
anticoagulant tests, dilute Russell’s viper venom time test, and for raised 
anticardiolipin antibodies by ELISA.  Of 35 women with recurrent fetal loss, 
seven were positive for LAC, 6 had increased IgG anticardiolipin antibodies, 
while of 31 women with only one or two fetal losses, one had LAC, none had 
increased IgG ACL antibody.  These were significant.  From this study it is 
concluded that lupus anticoagulant and increased IgG anticardiolipin antibodies 
are independently associated with recurrent first or second trimester fetal losses 
and such cases should be investigated. 
 Another study by Mac Lean et al., (1994) provides evidence of an 
association between lupus anticoagulant and raised anticardiolipin antibodies 
and early pregnancy loss.  A prospective study to determine the prevalence of 
lupus anticoagulant and raised anticardiolipin antibodies in women with two or 
more miscarriages in first trimester was conducted.  Two hundred and forty 
three women [113 had 2 miscarriages, and 130 had 3 or more miscarriages] 
were studied, of the 243 women tested, 16 (6.6%) were positive for LAC, 20 
(8.2%) had elevated ACL, and 5 (2%) had both the antibodies.  The most 
frequently positive tests were dilute Russell`s viper venom time and IgG for 
elevated anticardiolipin antibody. 
  
 
 A case control study conducted in Calcutta in 1996 by Bhattacharya et 
al., with 41 women with recurrent pregnancy wastages showed 19.5% of 
positivity for LAC.  The tests used were APTT and KCT.  This study also 
showed that the frequency of pregnancy wastage were more common in first 
and third trimester than second trimester. 
 Antiphospholipid antibodies can be detected in 1-5% of normal 
population without pregnancy loss.  This is similar to the study by Kutteh et 
al., (1996).  In this study, prevalence of antiphospholipid antibodies in general 
population was 4% and in women with recurrent pregnancy loss was 17.3%. 
 A case control study of the association between recurrent pregnancy loss 
and LAC and ACL was conducted by Gűllinnaz ALPER and colleagues 
(1999).  In this study 25 women with 2 or more consecutive unexplained 
spontaneous abortions and 15 women with one or more normal pregnancies 
without previous abortion were taken as cases and controls respectively.  
ELISA and APTT tests were performed.  Mann-Whitney non parametric test 
was used for analysis.  LA activity was detected in 5 (20%) of cases and none 
in controls.  Increased ACL levels were observed in 8 of 25 (32%) cases and 
one of 15 controls (7%). 
 Detection of antiphospholipid antibodies must be considered in women 
with previous pregnancies complicated by unexplained fetal wastages. 
  
 
 Chakrabarti et al., (1999), in his case control Study, found the 
prevalence of antiphospholipid antibodies on 50 pregnant women of first or 
second trimester with history of two or more unexplained pregnancy losses and 
30 pregnant women of same trimester without history of fetal loss.  LA was 
detected in 9 (18%) cases, and ACL in 12 (24%) cases of study group.  The 
control group was negative for any antibody.  The prevalence of antibodies in 
study group was statistically significant.  
Kumar et al., (2002), in his case control study at Hyderabad, found the 
incidence of antiphospholipid antibodies on 150 couples experiencing 3 or 
more recurrent pregnancy losses with similar number of matched controls.  
Using student’s test, LAC activity was found positive in 11 (10.28%) women 
and the binding of ACL antibodies to antigen was observed in 40.24% (n=33) 
of women.  
  This study suggested the usefulness of screening for these antibodies as a 
mandatory routine for a successful pregnancy outcome. 
 Zolghadri et al., (2004) determined the role of antiphospholipid 
antibodies as an etiological factor in recurrent pregnancy failure, in his 
prospective case control study on 138 women with history recurrent pregnancy 
loss and 100 well matched controls.  ACL antibody was measured by ELISA 
and LA by activated PTT.16 (11.6%) had positive ACL in cases, while 3 (3%) 
in controls were positive for ACL, P = 0.0157, OR= 4.24.LA was positive in 
  
 
12(8.7%) cases, and 3 (3%) controls.  P = 0.074, OR = 3.08.Overall 24 women 
(17.4%) were positive for one of the antibody, P = 0.0005, OR = 6.81.  Four 
were positive for both antibodies. 
This study emphasized the relationship between antiphospholipid 
syndrome and recurrent pregnancy failure. 
 Velayuthaprabhu et al., (2005) in a sequential Study, analyzed the 
prevalence of anticardiolipin antibody on 155 women with history of 3 or more 
recurrent spontaneous abortion in first trimester.  ELISA test was performed 
and analyzed by two tailed t-test to know the significance of ACL which was 
detected in 40% of cases. 
 Ghosh et al., (2006) in his study on 155 women with recurrent 
miscarriage/late pregnancy loss found a positive relationship of 27.7% for 
antiphospholipid antibody syndrome and recurrent pregnancy loss.  This was 
significant. 
 The significance of antiphospholipid antibodies in women with bad 
obstetric history was studied by Mishra et al., (2007) in Mumbai.  A 
prospective study on 120 women with bad obstetric history by ELISA for ACL, 
and anticoagulant tests for LAC was done.  This study showed a significant 
result of 28.3% and 15% of positivity for ACL and LAC respectively. 
  
 
 Another case control study was done by Indu Koul and colleagues 
(2007) in Jammu to assess the association of antiphospholipid antibodies in 
early repeated abortions. For detecting LA, prothrombin time, APTT, KCT 
were used and for ACL, ELISA was used.  Study population was 50 women 
without pregnancy loss and 50 patients with two or more previous pregnancy 
wastages in any trimester. Using Fisher test, statistical analysis was made.  
Among study group, 7 were positive for LAC, 5 were positive for ACL, P 
value for LAC = 0.012, for ACL = 0.056.  This was significant.  All the 
controls were negative for antibodies.   
This study also reported the association with early onset preeclampsia, 
intrauterine growth restriction and placental abruption. 
 A prospective study by Ajami et al., (2007) to detect the prevalence of 
IgG anticardiolipin antibody in recurrent pregnancy loss - Sari, concluded that 
the antibody is higher in second and third trimester of patients with recurrent 
fetal losses.  512 women in the age range of 18 -40 years (men 28.02 ± 5.66) 
were included.  ELISA test was performed.  ACL was detected in 57 (11.1%) 
cases (CI =2.7). 
  A retrospective study was conducted in Brazil,     by Spegiorin 
LCJF and colleagues (2010) to assess the prevalence of ACL antibody in 
patients with repeated miscarriages.  52 women with history of two or more 
miscarriages were evaluated, in the age range of 17-42, [mean age 26.7 years], 
  
 
ELISA test was performed. Fisher exact test was used for analysis.  
Abnormally high ACL antibody level was found in 55.7% of cases and LA in 
2% of cases. 
 Recently a study was conducted by Sarra Klai and colleagues (2010) to 
assess the association of antiphospholipid antibodies in pregnancy related 
complications.  302 women with pregnancy complications and 100 women 
with past history of uncomplicated pregnancies were screened for LAC and 
ACL antibodies .Significant association was found between antibody positivity 
and recurrent pregnancy loss (OR = 16.87, 95% CI, 5.5 – 51.63, P < 10-3) , 
intrauterine growth restriction (OR 3.9; 95% CI 1.08 -14.05, P = 0.04), 
Preeclampsia (OR = 15.31; 95% CI 1.25 – 16.42, P = 0.035).IgG was 
considered a risk factor for intrauterine growth restriction and recurrent 
pregnancy loss and LAC was associated with recurrent pregnancy loss alone. 
The assay for ACL antibodies is more sensitive and assay for LAC is 
more specific. 
Consensus guidelines recommend that at least 2 different phospholipid 
dependent assays should be used for screening and mixing studies with normal 
plasma should fail to correct the prolongation.  Other coagulopathies should be 
excluded.  The levels of LAC and ACL show spontaneous variation between 
pregnancy and non pregnancy, and even in the same pregnancy.  Hence a single 
  
 
abnormal test must be repeated after at least 8 weeks before it is considered 
clinically significant.  Although majority of patients with antiphospholipid 
syndrome have positive ACL and LAC, approximately 10-16% are positive for 
LAC and negative for ACL, 25% are positive for ACL and negative for LAC 
(17).  
The American College of Obstetricians and Gynecologists (ACOG) 
guideline of Management of Recurrent early pregnancy loss (2001) reached the 
following conclusion: 
Women with recurrent pregnancy loss should be tested for lupus 
anticoagulant and anticardiolipin antibodies using standard assays.  If test 
results are positive for the same antibody on two consecutive occasions 6 – 8 
weeks apart, the patients should be treated with heparin and low- dose aspirin 
during her next pregnancy attempt.  Mononuclear cell (leukocyte) 
immunization and intravenous immunoglobulin (IVIG) are not effective in 
preventing recurrent pregnancy loss.  
The Royal College of Obstetricians and Gynaecologists Guidelines on 
Management of Recurrent Miscarriage (2001) are consistent with ACOG 
Guidelines.  RCOG recommends, screening tests for antiphospholipid 
antibodies (both the lupus anticoagulant and anticardiolipin antibodies) 
  
 
performed on two separate occasions at least six weeks apart.  Discordant 
results should prompt the performance of a third test. 
 
Regarding management, those women with persistently positive tests for 
antiphospholipid antibodies are offered treatment with low dose aspirin 
together with low dose heparin during pregnancy (also the subject of on – 
going research). 
TREATMENT 
Treatment modalities are modified according to the type of 
antiphospholipid syndrome. Definite or Classic APS includes patients with 
LAC / medium to high titers of IgG/IgM ACL and fetal death, recurrent 
preembryonic or embryonic pregnancy loss, neonatal death after delivery for 
severe preeclampsia or fetal distress or thrombosis. 
Treatment options have evolved considerably.  Early enthusiasm for 
glucocorticoids waned when a small, randomized trial found heparin 
administered to pregnant women to be as effective as prednisone (18).  
Recently, two prospective trials showed that heparin plus low-dose aspirin is 
more effective than aspirin alone for achieving live births among women with 
antiphospholipid antibodies and predominantly preembryonic and embryonic 
  
 
pregnancy loss.  A  third prospective trial of women who were positive for 
antiphospholipid antibodies and has repeated pregnancy loss but no history of 
thrombosis or systemic lupus erythematosus found similar rates of live birth 
(approximately 80 percent) with the use of either low-dose aspirin or placebo, 
suggesting that treatment may be unnecessary in some women (19).   
Concern about patient selection notwithstanding, most experts recognize 
the antiphospholipid syndrome as a proven, treatable cause of recurrent 
pregnancy loss. Heparin and low dose aspirin treatment should be initiated after 
the identification of a viable pregnancy documented by ultrasound.  The 
recommended dose is Injection Heparin 15000-20000 units/day subcutaneously 
in divided doses with low dose aspirin 80 mg/day (20).  This should be 
combined with calcium and vitamin D supplementation to be continued 
postpartum (6 weeks). They can be switched over to warfarin postpartum. 
Low dose aspirin may improve pregnancy outcome by irreversibly 
blocking the cyclo-oxygenase in platelets, thereby inhibiting thromboxane 
synthesis. Heparin    may act by binding to phospholipid antibodies, thereby 
protecting the trophoblast phospholipids. 
 
 
  
 
Two types of immunotherapy have been explored; injections of paternal 
leukocytes (paternal white blood cell immunization or paternal cell 
alloimmunization) and the use of intravenous immunoglobulin (IVIG). 
Recent meta-analyses of randomized controlled trials of immunotherapy 
for recurrent miscarriage concluded that IVIG and paternal leukocyte injections 
provided no significant beneficial effect over placebo in preventing further 
miscarriages (Porter et al., 2006).  The investigators also found no significant 
benefit for other immunological treatment that has been used for recurrent 
miscarriage: third party donor cell immunization and trophoblast membrane 
infusion. 
An American Society for Reproductive Medicine (2004) Committee 
Opinion concluded that, IVIG as treatment of recurrent pregnancy loss should 
be evaluated in patients who are informed, consenting participants in an 
institutional review board approved randomized clinical trial.  For the 
management of recurrent spontaneous pregnancy loss IVIG is an experimental 
treatment.  
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AIM OF STUDY 
The aim of study is to screen for the presence of lupus anticoagulant 
antibodies and anticardiolipin antibodies in patients with unexplained recurrent 
pregnancy loss to evaluate the association.  
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MATERIALS AND METHODS 
 
Study Setup 
 This study on the screening for lupus anticoagulant and anticardiolipin 
antibody in women with unexplained recurrent pregnancy loss was a 
prospective analytical study undertaken at Institute of Social Obstetrics and 
Govt. Kasturba Gandhi Hospital for women and children, Chennai during 
December 2009- November 2010. 
Inclusion Criteria 
 Fifty antenatal mothers with previous history of two or more unexplained 
recurrent pregnancy losses were taken up for the study. 
Controls 
 The controls were 50 healthy pregnant women matched for age and 
gestational age with no history of previous abortions and have borne one or 
more live children. 
 
  
 
Exclusion criteria 
 The mothers with history of following conditions were excluded from the 
study. The conditions were, 
 Diabetes 
 Rh incompatibility 
 Endocrine causes 
 Genetic causes 
 Coagulation disorders 
 Sexually transmitted diseases. 
 Anemia 
 Hypertension 
 Uterine anomalies 
 Autoimmune disorders. 
 
Study design 
 For the selected number of patients, a careful detailed history was taken 
with special attention to previous obstetric history details regarding the 
previous pregnancy loss like abortion, intra uterine fetal death were recorded. 
Careful systemic and obstetric examinations were done.  
Routine and special investigations were done, these include 
  
 
 Urine :Albumin 
         Sugar 
       Deposits 
Culture and sensitivity 
 Haemogram and Packed cell volume 
 Platelet count 
 Blood grouping and Rh typing 
 Bleeding time and clotting time 
 Blood urea 
 Blood sugar 
 Serum creatinine 
 Serum uric acid 
 Plasma Fibrinogen 
 VDRL 
 HIV with consent 
 Ultra Sonogram 
 Endocrinologist opinion 
 Genetic opinion 
 Diabetologist opinion 
  
 
TEST FOR LUPUS ANTICOAGULANT ANTIBODY 
 
Procedure 
 Blood samples for coagulation studies were obtained by venepuncture, 
collected into glass tubes containing 3.8% trisodium citrate as the anti-
coagulant in the ratio 1 part anticoagulant to 9 parts of blood. For each study 
sample, one control sample was taken.  Platelet poor plasma was obtained by 
centrifuging blood for 15 minutes and used for LAC assays. The tests were 
done at Department of Biochemistry and Department of Rheumatology, 
Government General Hospital, chennai. 
The coagulation tests done for LAC were, 
1) Activated Partial Thromboplastin Time (APTT) 
2) diluted Russell Viper Venom Time (dRVVT) 
 
Activated Partial Thromboplastin Time  
Principle 
 The test measures the clotting time of test plasma after the addition of 
APTT reagent, then allowing activation time, followed by the addition of 
Calcium Chloride.  
  
 
  
 
 
 Deficiencies of approximately 40% and lower of factors VIII, IX, XI and XII 
will result in a prolonged APTT. Heparin in the presence of adequate amounts 
of AT-III will also result in a prolonged APTT. The APTT reagent contains a 
near colloidal particle activator (magnesium-aluminium silicate) for optimum 
sensitivity to factor deficiencies and to heparin. The reagent also contains a 
chloroform extract of rabbit brain with buffer and stabilizers (21). 
Materials used 
1. Platelet poor plasma – from both test and control cases 
2. Calcium chloride 0.025M 
3. APTT reagent 
4. Precision pipette 0.1ml 
5. Suitable timer 
6. Water bath at constant temperature of 37˚C 
Technique  
 The test plasma is prewarmed to 37˚C for 2 minutes. The APTT reagent 
is also prewarmed to 37˚C. 0.1 ml of reagent is forcibly added to 0.1ml of test 
plasma and this is incubated at 37˚C for exactly 5 minutes. To this, 0.1ml of 
  
 
0.025 M Calcium Chloride (prewarmed to 37˚C) is added and the time for clot 
formation is noted. The same procedure is repeated for the control plasma. The 
normal value is between 30-50 seconds, in LAC positive patients it is not 
correctable by 1:1 mixing with normal plasma. LAC is present if the difference 
in clotting times between the patient and control plasma is more than 10 
seconds. 
 
Dilute Russell`s Viper Venom Time 
Principle 
 Russell’s viper venom directly activates factor X in the presence of 
phospholipids and Calcium ions, bypassing factor VII of extrinsic pathway and 
the contact and antihaemophilic factors of the intrinsic pathway. In normal 
plasma in the absence of lupus anticoagulants, factor X is directly activated by 
Russell’s viper venom, which in the presence of phospholipid and calcium ions 
leads to clot formation. In patients with LAC, auto antibodies bind the epitopes 
of reagent phospholipids thereby preventing the activation of prothrombinase 
complex. This results in a prolongation of clotting time. 
 
  
 
  
 
Materials used 
1) Platelet poor plasma-from both test and control cases 
2) LA screen and LA confirm reagents-lyophilized preparations 
containing Russell’s viper venom enriched with phospholipid at 
different concentrations, with 0.01% thiomersal as preservative. 
3) Calcium chloride 0.025M 
4) 0.1ml precision pipettes 
5) Stopwatch 
6) Glass test tubes 
7) Water bath 
 
Technique 
 All reagents should be brought to room temperature before prewarming 
at 37˚C for testing purpose .0.1ml of LA screen reagent is added to 0.1ml of 
platelet poor plasma, contents mixed and incubated at 37˚C for 3 minutes. To 
this, 0.1ml of calcium chloride is added (prewarmed at 37˚C for 10 minutes), 
and the time for clot formation is noted. If this screen time is less than 35 
seconds, it indicates absence of LA and there is no need to perform the 
confirmatory test. If the screen time is more than 35 seconds, the same 
procedure is repeated with LA confirm reagent (this reagent incorporates 
  
 
additional phospholipids to neutralize LA, thereby achieving a lower clotting 
time, thus proving the phospholipid dependence of the auto antibodies) (21). 
TEST FOR ANTICARDIOLIPIN ANTIBODY-ELISA 
Principle 
Enzyme immunoassay measures the enzyme labeled antigen, hapten, or 
antibody. It is of 2 types. (Homogenous and heterogeneous). ELISA is the 
heterogeneous EIA, requires the separation of free and bound fractions either 
by centrifugation or by absorption on solid surfaces and washings. The reagents 
are added sequentially. 
Materials used 
1. Serum from test and control cases 
2. Microtitre plates 
3. Cardiolipin 
4. Blocking buffer 
5. Horse raddish peroxidase 
6. Hydrogen peroxide 
7. Stop solution. 
  
 
  
 
Technique 
 Serum is the recommended sample for ACL evaluation. Anticardiolipin 
antibody estimation is done by ELISA method (Harris et al). Individual 96 
well micro titer plates are coated with 30 ml of cardiolipin at a concentration of 
45 mg per ml and blocked with 200 ml of blocking buffer containing 10% fetal 
calf serum for 2 hours. 50ml of test samples in 1:150 dilutions with PBS are 
added to react. After washing, equal amounts of purified Horse raddish 
peroxidase is added and allowed to react for 3 hours at 4˚C. Again plates are 
washed. H2O2 is added at 56˚C until the blue color is obtained, then stop 
solution is added and read at 405nm. The result is interpreted in GPL units or 
MPL units (<10-negative, 10-19-Borderline, 20-80 positive, >80 – high 
positive) (22). 
 
  
 
 
 
 
 
 
DATA ANALYSIS 
 
 
 
 
 
  
 
DATA ANALYSIS 
The present study of screening for the presence of lupus anticoagulant and 
anticardiolipin antibodies in recurrent pregnancy loss was carried out on 50 
pregnant women with previous two or more pregnancy wastages. The tests 
were also performed on 50 controls. The various observations from this study 
were analyzed using chi-square test wherever necessary and the results were 
tabulated here. 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table-1  
Age Distribution of all cases  
Age in Yrs No. of Patients % 
≤ 20 3 6% 
21-24 18 36% 
25-29 19 38% 
≥30 10 20% 
 50 100% 
 
This table shows the age distribution of cases. The maximum number of 
patients fell into 25 - 29 years (38%) age group.36 % belonged to 21-24 years, 
20% to > 30 years, and six percentage to < 20 years age group. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
Table-2 
Comparison of age distribution of cases and controls 
Age in Years Cases  Controls 
≤20 3 3 
21-24 18 16 
25-29 19 21 
≥30 10 10 
 
Mean 25.92 25.98 
SD 4.125 4.138 
P=0.975 
This table shows that the age distribution of cases and controls with the 
maximum number of cases falling in the age group 25-29 years. The cases and 
controls are comparable with age. 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
Table-3 
Conception distribution of cases  
Gravida No .of cases % 
3 13 26% 
4 25 50% 
5 12 24% 
 
This table shows that among the cases, maximum number were Gravida IV 
(50%), 26%were Gravida III, 24%were Gravida V. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table-4 
Comparison of Gestational age of cases and controls 
Trimester Cases Controls 
First 5 4 
Second 38 38 
Third 7 8 
 
Mean 22.02 22.48 
SD 6.022 6.072 
P=0.969 
This table shows that maximum number of patients were in second trimester. 
 
 
  
 
 
 
 
 
S.No Age Parity G.A LAC tests ACL tests Pregnanc
Outcome
  
 
Table -5 
Antibodies positive cases and controls 
G.A=gestational age. 
Among cases, 5 were positive for LAC, 7 were positive for ACL.   
Among controls, 2 were positive for LAC, 1 was positive for ACL. 
 
 
APTT dRVVT IgM IgG 
Study Control Study Control     
1 24 G5P2L0A2 14 54 35 52 36 Absent Present A 
2 26 G5P0L0A4 18 60 32 58 33 Absent Present A 
3 29 G3P2L0A0 28 52 32 55 36 Absent Present FD 
4 33 G4P0L0A3 20 58 40 55 34 Absent Present A 
5 30 G5P2L1A2 17 69 40 58 40 Absent Present LB 
6 21 G4P0L0A3 16 34 32 35 31 Absent Present LB 
7 28 G3P0L0A2 26 36 34 32 30 Absent Present LB 
8 30 G3P2L2 28 56 36 52 37 Absent Absent LB 
9 28 G2P1L1 32 54 34 52 38 Absent Absent LB 
10 27 G2P1L1 12 36 37 35 34 Absent Present LB 
            
           
  
 
 
Table-6 
Lupus anticoagulant antibodies positive patients (APTT and dRVVT test) 
 No. of Test 
positives 
No. of Test 
negatives 
Total 
Cases 5 45 50 
Controls 2 48 50 
Total 7 93 100 
Sensitivity=71.42% 
Specificity=51.61% 
Positive Predictive Value=10% 
Negative Predictive Value=96% 
False Negative=28.57% 
False Positive=48.38% 
The same 5 patients were positive for APTT and dRVVT test. 
 
Table-7 
  
 
Anticardiolipin antibodies positive patients (ACL IgG assay) 
 No. of Test 
positives 
No. of Test 
negatives 
Total 
Cases 7 43 50 
Controls 1 49 50 
Total 8 92 100 
Sensitivity=87.5% 
Specificity=53.26% 
Positive Predictive Value =14% 
Negative Predictive Value =98% 
False Negative =12.5% 
False Positive =46.73% 
 
 
 
 
 
  
 
Table-8  
Comparison of ACL test with LAC tests 
Tests  Patients positive 
for ACL 
Patients negative 
for ACL 
Total 
Patients positive 
for LAC 
5 2 7 
Patients negative 
for LAC 
3 90 93 
Total 8 92 100 
 
Sensitivity=62.5%  
Specificity=97.82%  
Positive Predictive Value=71.42%  
Negative Predictive Value=96.77%  
  
 
 
 
  
 
Table-9 
Previous Pregnancy Outcome of all Cases 
Type of Loss Numbers % 
Abortion 111 74.49% 
Fetal death 32 21.47% 
Live birth 6 4.02% 
 149  
 
Among the total number of fetal losses 74.49% (n=111) were abortions, 
21.47% were fetal deaths (n=32). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Table-10 
  
 
Previous abortions of all cases. 
No .of abortions No .of cases % 
1 5 10.2% 
2 27 55.1% 
3 16 32.6% 
4 1 2.0% 
 
This table shows 55.1% of cases had two abortions and 32.6% had three 
abortions. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
Table-11 
 
Present Pregnancy outcome in cases and controls 
Outcome Cases Controls 
Fetal loss 4 0 
Live birth 46 50 
P=0.041 
 
Among cases, 46 patients gave birth to live children, 3 had abortions and one 
had fetal death. All the controls gave birth to live children 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
Table-12 
Present pregnancy outcome in LAC positive cases 
 
Outcome No. of  cases %. 
Abortion 3 60% 
Fetal death  1 20% 
Live birth 1 20% 
 
Among 5 LAC positive cases 60% had abortions, 20% had fetal deaths and 
20%delivered live children. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
Table-13 
Present pregnancy outcome in ACL positive cases 
 
Outcome No. of  cases %. 
Abortion 3 42.85% 
Fetal death  1 14.28% 
Live birth 3 42.85% 
 
Among 7 LAC positive cases 42.85% had abortions, 14.28% had fetal deaths 
and 42.85%delivered live children. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
Table-14 
 Gestational age and present pregnancy loss 
 
Gestational age No. of losses % 
First trimester 0 0 
Second trimester 3 42.8% 
Third trimester 1 14.2% 
 
This table shows 42.8% of pregnancy losses were in second trimester, and 
14.2% were in third trimester.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
Table-15 
Previous &Present pregnancy outcome in APS cases 
 
Pregnancy 
outcome 
Previous 
pregnancy 
% Present 
pregnancy 
% 
Abortion 16 72.72% 3 42.85% 
Fetal death 5 22.72% 1 14.28% 
Live birth 1 4.5% 3 42.85% 
P=<0.05 
APS-antiphospholipid syndrome. 
 
 
 
 
 
  
 
 
 
Table-16  
Obstetric complications in previous pregnancy.  
 
IUGR-intrauterine growth restriction 
IUFD-intrauterine fetal death 
PTL-preterm labour 
 
 
 
Complications  All cases % Antibody 
positive cases 
% P value 
Abortions 111 74.49% 16 72.72% 0.00 
Preeclampsia 35 23.48% 11 50% 0.00 
IUGR 5 3% 2 9% 0.005 
abruption 5 3% 2 9% 0.005 
IUFD 32 21.47% 5 22.72% 0.00 
PTL 2 1.34% 1 4.54% 0.05 
  
 
 
 
Table-17  
Obstetric complications in present pregnancy. 
Complications  No % 
Abortions 3 60% 
Preeclampsia 2 40% 
IUGR 1 20% 
abruption 0 0% 
IUFD 1 20% 
PTL 1 20% 
 
In the present pregnancy the occurrence of preeclampsia was found to be 40% 
and none reported to have abruption. 
 
 
 
  
 
 
 
 
 
 
 
DISCUSSION 
  
 
 
 
DISCUSSION 
Recurrent pregnancy loss is defined as three or more consecutive losses 
which occurs approximately one in three hundred pregnancies (23). Clinical 
investigations may be initiated after two consecutive spontaneous losses, 
because in patients with recurrent pregnancy loss, the risk of subsequent 
pregnancy loss is 24%after two losses, 30%after three losses, and 40-50%after 
four losses (24).  
Of  the 100 patients who were screened for lupus anticoagulant 
antibodies using APTT and dRVVT tests, and anticardiolipin antibodies using 
ELISA, at Institute of Social Obstetrics and Govt. Kasturba Gandhi Hospital, 
Chennai,  among patients with recurrent pregnancy loss, five cases were 
positive for lupus anticoagulant antibody, seven cases were positive for 
anticardiolipin  antibody.  Using APTT and dRVVT tests for detecting lupus 
anticoagulant antibody, the same five cases were positive for both the tests.    
All the patients were negative for test for anticardiolipin with IgM assay.  
Among the control patients (without pregnancy loss) two had positive results 
for lupus anticoagulant and one had positive result for anticardiolipin antibody. 
 
  
 
Table-1&2  shows that ,majority of patients were in the age group of 25-
29 years [cases – 38%, controls 42%].  The mean age for patients with 
recurrent pregnancy loss was 25.92 ± 4.12, and for patients without recurrent 
pregnancy loss was 25.98 ± 4.13.   
P = 0.975, thus the age distribution between the cases and controls were 
comparable.  
This is similar to the study conducted at Brazil by Ligia et al (2010), 
where the mean age of the cases were 26.7 years.   
 
Table-3 shows the conception distribution as follows: Among the cases, 
majority were gravida IV (50%), 26% were gravida III, 24% were gravida V.  
In control group, 88% were gravida II, 10% were gravida III and two 
percentages were gravida IV. 
 
As shown in table 4, the study and control groups were comparable in 
gestational age at which the tests were done.  Among the cases, 5 (10%) were 
in first trimester, 38 (76%) were in second trimester, 7 (14%) were in third 
trimester.  In the control group, 4 (8%) were in first trimester, 38(76%) were in 
second trimester, 8(16%) were in third trimester .p = 0.969. 
 
Table-6 shows that seven patients showed prolongation of APTT and 
dRVVT tests, of which 5 were cases, 2 were controls. Sensitivity of these both 
  
 
tests were 71.42%, specificity was 51.61%, predictive value for positive test 
was 10%, and predictive value for negative test was 96%. The percentage of 
false positive for both tests was 48.38% false negative was 28.57%. The two 
patients in control group with test positive results had no previous or present 
pregnancy fetal wastages. The 5 patients with recurrent pregnancy losses were 
positive for both the tests. Among the 5 cases, three had abortions, one had 
fetal death, and one delivered a live child during present pregnancy. The 
Incidence of lupus anticoagulant antibody in our study was 10%. The relative 
risk for pregnancy loss due to LAC was 1.4 [i.e., there was 1.4 fold increased 
risk for fetal loss with LAC]. 
 All the patients (both cases and controls) had negative results for IgM 
assay for anticardiolipin antibody. 
 
Table-7 shows that eight patients were positive for anticardiolipin test 
with IgG assay, of which 7 were study cases, 1 was in control group. 
Sensitivity of the test was 87.5%, specificity was 53.26%. Predictive value for 
positive test was 14% and predictive value for negative test was 98%. The 
percentage of false positive was 46.73% and false negative was 12.5%.  
The patient in control group had no pregnancy wastage. Among the 7 
cases, three had abortions, one had fetal death, and three delivered live 
children. The Incidence of anticardiolipin in our study was 14%. The relative 
  
 
risk for pregnancy loss with ACL was 1.8 [i.e., there was 1.8fold increased risk 
of fetal loss with ACL].  
Creagh et al (1991) studied 35 women with recurrent pregnancy loss 
and found 20%incidence for lupus anticoagulant and 17.1%incidence for 
anticardiolipin antibody.  
MacLean et al (1994) studied 243 women and reported an incidence of 
6.6%for lupus anticoagulant and 8.2%for anticardiolipin antibody.  
Kumar et al (2002) studied 150 women and the incidence in the study 
was 10.28%for lupus anticoagulant and 40.24% for anticardiolipin antibody. 
Velayuthaprabhu et al (2005) studied 155 women and the incidence 
was 14% for lupus anticoagulant and 40%for anticardiolipin antibody. 
 Mishra et al (2007) studied 120 women and reported an incidence of 
15%for lupus anticoagulant and 28.3%for anticardiolipin antibody. 
  The incidence of lupus anticoagulant in our study was 10% and for 
anticardiolipin antibody, it was 14%.  
Comparison with Previous studies 
  
 
 
Studies No. of 
patients 
LAC % ACL% 
Creagh et al 
1991 
35 20 17.1 
MacLean et al 
1994 
243 6.6 8.2 
Kumar et al 2002 150 10.28 40.24 
Velayuthaprabhu 
et al 2005 
155 14 40 
Mishra et al 
2007 
120 15 28.3 
Present 50 10 14 
Comparing the test for anticardiolipin using ELISA with test for lupus 
anticoagulant using coagulation tests, test for ACL had a sensitivity of 62.5%, 
specificity of 97.82%, and predictive value for positive test of 71.42%, 
predictive value for negative test of 96.77% (table-8). The predictive value of 
the test for anticardiolipin can be improved with combining both the tests. 
  
 Table-9 shows the pregnancy wastages in previous pregnancy among all 
cases. There were 74.49% of abortions and 21.47% of fetal deaths. 
 
  
 
 Table 10 shows the number of abortions in previous pregnancy of all 
cases. Ten percentages had one prior abortion, 54.55% had two prior abortions, 
32.65% had three previous abortions and two percent had 4 abortions. 
   
As shown in table-11, the present pregnancy outcome was compared between 
all cases and controls. Forty six  patients in the study group gave birth to live 
children, four had fetal losses among them, and all 50 in control group gave 
birth to live children( p = 0.041).  
The results showed the significant association between pregnancy 
outcome and presence of lupus anticoagulant and anticardiolipin antibodies.  
 
Table-12&13: 
In the present pregnancy, among LAC positive cases, 60% had abortions, 
20% had live births, another 20% had fetal deaths (p = 0.08).Among ACL 
positive cases, 42.85% had abortions ,14.28% had fetal deaths and 42.85% 
delivered live children( p=0.154).  
 
As shown in table -14, in the present study 42.8 % were second trimester 
losses and 14.2% of losses were in third trimester.  
 
Chakrabarthi’s study reported that 73.1% were first trimester losses, 
26.9% were second trimester losses. 
  
 
  
Thind et al reported 23% abortions, 57.3% intrauterine deaths. 
  
Branch et al, reported 50-60% of losses in first trimester, 30% in second 
trimester, 10-28% in third trimester.  
 
As shown in table-15, among the seven antiphospholipid antibody 
positive cases 72.72% were abortions, 22.72% were fetal deaths and 4.5% were 
live births during previous pregnancy.   During present pregnancy, 42.85% 
were abortions, 14.28% were fetal deaths and 42.85% were live births. 
Table-16&17 shows that out of 22 previous pregnancies, 11 had 
preeclampsia, (p = 0.00), 16 had abortions, (p = 0.00), 2 had intrauterine 
growth restriction (p = 0.005), 2 had abruption (p = 0.005), and 5 had 
intrauterine fetal deaths (p = 0.00). The incidence of these obstetric 
complications had a significant association with antibody positivity. The 
incidence of preterm labour was 1.34% in all cases, 4.54% in positive cases 
(p=0.05). 
  
In present pregnancy, 3 cases had abortions, 2 had preeclampsia, and 1 
had an intra uterine death of fetus, 1 had preterm labour and another one 
delivered a growth retarded baby.  There were no incidences of abruption in the 
present pregnancy. 
  
 
 
The present study shows that lupus anticoagulant and anticardiolipin 
antibodies are significantly associated with repeated pregnancy losses. 
  
All the 7 cases with antiphospholipid antibodies, once they were detected 
to be antibodies positive, they were put on heparin and aspirin treatment. The 
dosage was Injection Heparin 5000units subcutaneously twice daily along with 
Tablet Aspirin 75mg once daily. The outcome was as follows: out of the 5 
patients detected in second trimester, 3 had abortions, 2 had live births. Out of 
the 2 detected in third trimester, 1 had fetal death, 1 had live birth. Since our 
study was mainly a screening test, the details of treatment were not taken in to 
account for the evaluation of results and outcome. However counseling was 
given and patients were advised to report as soon as they miss the period in 
future pregnancy. 
  
Women with lupus anticoagulant and anticardiolipin antibodies have a 
significant risk of reproductive failure, and adverse pregnancy outcome like 
recurrent abortions, intra uterine fetal death and intra uterine growth 
retardation. Women with history of thrombosis, or unexplained pregnancy loss 
should be screened for lupus anticoagulant and anticardiolipin antibodies along 
with maternal and fetal surveillance for a successful pregnancy outcome. 
 
  
 
 
 
 
 
 
 
 
 
 
SUMMARY 
  
 
 
SUMMARY 
The present study was a prospective study aimed at screening for the 
presence of lupus anticoagulant and anticardiolipin antibodies in 50 patients 
with history of recurrent pregnancy losses and 50 controls matched for age, 
gestational age at study, of proven good reproductive history. 
  The distribution of study cases were 10% in first trimester, 76% in 
second trimester, and 14% in third trimester. 
 The tests done were Activated Partial Thromboplastin Time and diluted 
Russell Viper Venom Time for lupus anticoagulants and ELISA for 
anticardiolipin antibodies. 
 Five cases (10%) were positive for lupus anticoagulant, seven cases 
(14%) were positive for anticardiolipin antibodies. Hence the incidence of LAC 
and ACL in our study population was 10% and 14% respectively. The relative 
risk for pregnancy loss due to lupus anticoagulant was 1.4 and for 
anticardiolipin antibody, the relative risk was 1.8. 
 Both APTT and dRVVT tests were sensitive in detecting lupus 
anticoagulant antibodies, but test for anticardiolipin had more specificity in our 
study.  
 
The outcome of LAC positive cases during previous pregnancy was as 
follows: 64.7% were abortions, 29.41% were fetal deaths, and 5.88% were live 
  
 
births. During present pregnancy 60% were abortions, 20% were fetal deaths, 
20% were live birth. 
The outcome of ACL positive cases during previous pregnancy was as 
follows: 72.72% were abortions, 22.72% were fetal deaths and 4.5% were live 
birth. During present pregnancy 42.85% were abortions, 14.28% were fetal 
deaths, 42.85% were live births. Other pregnancy related complications noted 
were: 
a) Preeclampsia; 50% of cases had preeclampsia in their previous 
pregnancy, 40% of cases had during present pregnancy. 
b) IUFD: 22.72% of cases had intra uterine fetal death during previous 
pregnancy and 20% of cases had intrauterine fetal death during present 
pregnancy. 
c) IUGR: 9% of cases had growth retarded babies in previous pregnancy 
and one had growth retarded baby during present pregnancy. 
d) Preterm labour: 4.54% of cases had preterm labour during previous 
pregnancy and one had it during present pregnancy. 
e) Abruptio placenta: 9% of cases had abruption during previous pregnancy 
and none had abruption during present pregnancy. 
  
 
 
 
 
 
CONCLUSION 
 
  
 
CONCLUSION 
 The presences of antiphospholipid antibodies [lupus anticoagulant and 
anticardiolipin] are associated with adverse pregnancy outcome. Patients with 
recurrent pregnancy loss need to be subjected to investigations for these 
antibodies. 
 Identification of those patients early, with early institution of therapy will 
help in minimizing the associated complications and pregnancy losses, thus 
aiding the anxious mother in delivering a live child. 
 The commonly used tests for detection of these antibodies are activated 
partial thromboplastin time and dilute Russell`s viper venom time for lupus 
anticoagulant and ELISA for  anticardiolipin since performing  more than one 
lupus anticoagulant screening test is important for optimal sensitivity. 
Moreover the predictive value of testing with anticardiolipin ELISA can be 
improved to an extent by concurrent lupus anticoagulant testing. 
 In combination, these tests are sensitive, specific which can be used in 
conjunction to screen the patients with recurrent pregnancy loss and are 
mandatory in the investigation protocol for these patients in order to prevent 
further pregnancy wastages. 
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PROFORMA 
 
 
  
 
PROFORMA 
SCREENING FOR LUPUS ANTICOAGULANT ANTIBODY AND 
ANTICARDIOLIPIN ANTIBODY IN RECURRENT PREGNANCY LOSS. 
Name    : 
Age    : 
IP No    : 
Unit    : 
Gravida   : 
Para     :               
Live     :         
 Abortion    : 
Socioeconomic status : 
Education   : 
L.M.P    : 
E.D.D    : 
Gestational age  : 
Booked/Immunised : 
Menstrual history  : 
 Age at menarche : 
Periods : 
 
Marital history  : 
M/S   : 
  
 
Consanguinity : 
Obstetric history  : 
 Past   : 
Present  : 
 Risk factors  : 
H/O hypertension  : 
H/O drug intake  : 
H/O diabetes  : 
H/O Rh incompatibility : 
H/O SLE   : 
H/O autoimmune  
Disorders   : 
Past history   : 
 Medical  : 
Surgical  : 
Personal history  : 
Family history  : 
General examination : 
 Built   : 
 Nourishment : 
 Anaemia  : 
Pedal edema : 
Jaundice  : 
  
 
Goiter  : 
Breast  : 
Spine   : 
Features of SLE/ 
Autoimmune 
Disorders  : 
Height  : 
Weight  : 
BMI   : 
Vital signs   : 
 Temp:                  PR: 
 RR     :                  BP: 
Systemic examination : 
CVS   : 
RS   : 
CNS   : 
P/A   : 
P/V   : 
 
Investigations  : 
Urine albumin : 
 Sugar  : 
Deposits : 
  
 
C&S  : 
Complete Haemogram : 
  Hb  : 
  RBC  : 
PCV  : 
TC  :  
DC  : 
PLATELETS :  
Bleeding time : 
Clotting time : 
Blood urea   : 
Sugar   : 
Serum creatinine  : 
 Uric acid  : 
 Proteins  : 
Plasma fibrinogen  : 
VDRL    : 
HIV    : 
Blood group&type  : 
USG abdomen  : 
Endocrinologist`s 
 Opinion   : 
Diabetologist `s opinion : 
  
 
Geneticist`s opinion : 
LAC result 
 APTT   : 
 dRVVT  : 
ACL result  
IgM   : 
IgG   : 
  
 
 
 
 
 
MASTER CHART
  
 
             
   
MASTER CHART FOR CASES 
   
S.No Name Age I.P.No: Parity G.A 
LAC tests aCL test 
Pregnancy 
Outcome APTT dRVVT IgM IgG 
Study Control Study Control   
1 Selvi 26 12326 G3P0L0A2 18 33 35 35 33 Absent Absent LB 
2 Ayesha 31 13777 G4P1L0A2 18 34 37 35 32 Absent Absent LB 
3 Nathiya 18 13806 G4P1L0A2 22 38 40 32 34 Absent Absent LB 
4 Gousiabegum 22 13912 G5P1L1A3 11 34 32 34 36 Absent Absent LB 
5 Maheswari 27 14111 G3P1L0A1 24 35 38 36 34 Absent Absent LB 
6 Daisy Raju 34 14214 G4P2L0A1 24 33 31 34 31 Absent Absent LB 
7 Aathilakshmi 24 12287 G5P2L0A2 14 54 35 52 36 Absent Present A 
8 Senthamari 28 15101 G4P1L0A2 28 36 37 30 32 Absent Absent LB 
9 Anitha 32 14011 G4P2L0A1 23 36 34 32 35 Absent Absent LB 
10 Salima Banu 21 14927 G3P0L0A2 29 35 33 30 33 Absent Absent LB 
11 Priya 21 14172 G3P0L0A2 25 32 35 34 36 Absent Absent LB 
12 Jaya 25 13119 G4P1L0A2 28 34 38 34 32 Absent Absent LB 
13 Gayathri 26 13911 G5P0L0A4 18 60 32 58 33 Absent Present A 
14 Jothi 22 14221 G5P1L1A3 26 36 40 34 30 Absent Absent LB 
15 Lakshmi 23 13992 G4P1L0A2 12 34 40 32 31 Absent Absent LB 
16 Mumtaz 20 14217 G4P0L0A3 18 32 38 30 32 Absent Absent LB 
17 
Humera 
Begum 33 15105 G3P0L0A2 30 38 37 30 34 Absent Absent LB 
18 Vembuli 29 13333 G3P2L0A0 28 52 32 55 36 Absent Present FD 
19 Revathi 31 13897 G4P1L0A2 16 35 31 34 32 Absent Absent LB 
20 Sasikala 27 14288 G4P0L0A3 19 30 32 35 33 Absent Absent LB 
21 Glory 23 12927 G5P2L1A2 22 34 32 35 32 Absent Absent LB 
22 Vimala 35 13827 G3P0L0A2 24 36 34 32 34 Absent Absent LB 
23 Jaya Lakshmi 27 13914 G4P2L0A1 32 36 34 37 35 Absent Absent LB 
24 Amutha 30 12906 G4P2L0A1 24 36 39 34 33 Absent Absent LB 
25 Kamala 22 14111 G3P0L0A2 26 32 30 35 34 Absent Absent LB 
  
 
 
 
26 
Thirumala 
devi 21 12114 G4P0L0A3 16 34 32 35 31 Absent Present LB 
27 Parveen 27 12346 G4P1L0A2 10 32 30 34 30 Absent Absent LB 
28 Yasmin banu 22 13118 G5P1L0A3 18 36 31 35 36 Absent Absent LB 
29 Karpagam 26 12916 G4P1L0A2 30 36 37 32 34 Absent Absent LB 
30 Vimala 26 13416 G5P2L0A2 22 34 39 34 33 Absent Absent LB 
31 Rani 29 12876 G4P0L0A3 24 38 40 35 32 Absent Absent LB 
32 Rajeswari 24 14110 G5P1L1A3 32 34 32 36 35 Absent Absent LB 
33 Rajmma 32 13191 G4P1L0A2 16 35 36 34 33 Absent Absent LB 
34 Santhi 33 14625 G4P0L0A3 20 58 40 55 34 Absent Present A 
35 Kavitha 23 14127 G4P0L0A3 26 36 38 32 36 Absent Absent LB 
36 Kalyani 23 12356 G3P0L0A2 28 32 37 32 35 Absent Absent LB 
37 Yogalakshmi 19 13671 G4P0L0A3 11 38 34 35 32 Absent Absent LB 
38 Ammu 28 13238 G3P0L0A2 26 36 34 32 30 Absent Present LB 
39 Anbarasi 21 12428 G3P0L0A2 33 32 33 34 31 Absent Absent LB 
40 Alima 27 13761 G5P2L0A2 27 36 34 30 32 Absent Absent LB 
41 RajaLakshmi 30 13573 G5P2L1A2 17 69 40 58 40 Absent Present LB 
42 Saraswathi 22 14615 G5P2L0A2 18 36 32 32 34 Absent Absent LB 
43 Santhimeena 26 14884 G4P0L0A3 16 35 32 34 32 Absent Absent LB 
44 Pavithra 27 15111 G4P0L0A3 20 32 34 35 32 Absent Absent LB 
45 Ponnamal 23 12500 G4P1L0A2 22 36 32 32 36 Absent Absent LB 
46 Parimala 25 12715 G3P0L0A2 22 38 39 33 38 Absent Absent LB 
47 Rooba 29 13428 G4P0L0A3 12 40 37 34 31 Absent Absent LB 
48 Poovazhagi 24 12617 G5P1L1A3 20 36 32 32 34 Absent Absent LB 
49 Ponni 28 12702 G3P0L0A2 26 34 32 30 33 Absent Absent LB 
50 Prabha 24 13716 G4P0L0A3 30 38 40 35 34 Absent Absent LB 
  
 
 
   MASTER CHART FOR CONTROLS 
  
 
S.No Name Age I.P.No: Parity G.A 
LAC tests aCL test 
Pregnancy 
Outcome APTT dRVVT IgM IgG 
Study Control Study Control 
  
1 Ramya 21 12666 G2P1L1 20 34 32 35 34 Absent Absent LB 
2 Kamala 29 12895 G2P1L1 24 31 35 32 32 Absent Absent LB 
3 Yuvarani 24 12421 G2P1L1 24 35 37 32 36 Absent Absent LB 
4 Ambika 30 12440 G3P2L2 28 56 36 52 37 Absent Absent LB 
5 Aruna 17 12323 G2P1L1 18 34 37 32 38 Absent Absent LB 
6 Devi 28 12682 G2P1L1 16 35 35 34 35 Absent Absent LB 
7 Deepa 27 12445 G2P1L1 28 36 34 36 37 Absent Absent LB 
8 Anjalai 26 12544 G2P1L1 14 32 35 38 36 Absent Absent LB 
9 Bagya 31 12899 G2P1L1 22 34 32 36 38 Absent Absent LB 
10 Chitra 23 12545 G2P1L1 28 35 34 32 35 Absent Absent LB 
11 Shenbegum 34 12684 G3P2L2 11 34 31 34 37 Absent Absent LB 
12 Seetha 24 12665 G2P1L1 26 35 32 36 38 Absent Absent LB 
13 Radha 25 12768 G2P1L1 24 35 34 35 37 Absent Absent LB 
14 Nirmala 32 12678 G2P1L1 29 34 35 35 34 Absent Absent LB 
15 Amudha 22 13918 G2P1L1 18 34 37 35 33 Absent Absent LB 
16 Barani 26 12889 G2P1L1 16 33 36 35 32 Absent Absent LB 
17 Kalaiselvi 35 13137 G4P3L3 14 35 38 34 30 Absent Absent LB 
18 Tamilselvi 19 13158 G2P1L1 18 35 32 38 40 Absent Absent LB 
19 Sundari 28 12679 G2P1L1 32 54 34 52 38 Absent Absent LB 
20 Thangamani 29 13188 G2P1L1 22 34 33 35 37 Absent Absent LB 
21 Stella 21 12892 G2P1L1 20 34 31 34 36 Absent Absent LB 
22 Bhavani 27 13199 G2P1L1 20 37 30 34 37 Absent Absent LB 
23 Sivagami 26 12680 G2P1L1 24 38 40 32 35 Absent Absent LB 
24 Sankari 23 13200 G2P1L1 32 38 38 35 34 Absent Absent LB 
25 Amsa 31 12688 G2P1L1 24 35 37 34 32 Absent Absent LB 
  
 
 
 
26 Geetha 22 12919 G2P1L1 10 35 32 35 33 Absent Absent LB 
27 Prema 26 14811 G2P1L1 16 34 31 34 35 Absent Absent LB 
28 Selvi 21 14872 G2P1L1 30 36 34 36 37 Absent Absent LB 
29 Jayanthi 25 12877 G2P1L1 18 35 33 34 36 Absent Absent LB 
30 Dhanalakshmi 26 15112 G2P1L1 18 35 34 35 37 Absent Absent LB 
31 Sumathi 24 12927 G2P1L1 24 32 35 36 38 Absent Absent LB 
32 Pushpa 23 14119 G2P1L1 28 34 36 35 33 Absent Absent LB 
33 Alamelu 27 13976 G2P1L1 12 36 37 35 34 Absent present LB 
34 Maha 27 12999 G2P1L1 26 37 38 34 35 Absent Absent LB 
35 Sudha 22 12690 G2P1L1 26 35 34 34 32 Absent Absent LB 
36 Megala 24 12222 G2P1L1 30 32 35 35 33 Absent Absent LB 
37 lakshmi 29 13999 G3P2L2 28 35 33 35 34 Absent Absent LB 
38 Kala 29 12976 G2P1L1 22 36 34 38 36 Absent Absent LB 
39 Nirosha 27 12333 G2P1L1 24 34 32 36 38 Absent Absent LB 
40 Raji 18 12787 G2P1L1 28 35 31 37 39 Absent Absent LB 
41 Sundara 33 13912 G3P2L2 26 36 34 38 40 Absent Absent LB 
42 Valli 23 13334 G2P1L1 12 35 32 35 33 Absent Absent LB 
43 Dhiya 32 12114 G2P1L1 22 32 34 34 32 Absent Absent LB 
44 Kavya 28 13378 G2P1L1 32 35 33 34 35 Absent Absent LB 
45 Sumathi 31 12771 G3P2L2 20 34 32 36 37 Absent Absent LB 
46 Ganga 30 13414 G2P1L1 18 30 34 34 36 Absent Absent LB 
47 Vanitha 21 13578 G2P1L1 16 33 31 35 37 Absent Absent LB 
48 Gowri 26 12116 G2P1L1 24 32 30 35 38 Absent Absent LB 
49 lalitha 22 12888 G2P1L1 28 35 32 34 34 Absent Absent LB 
50 sindhu 25 13771 G2P1L1 34 35 33 35 33 Absent Absent LB 
  
 
ABBREVIATIONS 
ACL-  Anticardiolipin 
ACOG- American College of Obstetricians and Gynecologists 
APS-  Antiphospholipid antibody syndrome 
APTT- Activated partial thromboplastin time 
dRVVT- dilute Russell`s viper venom test 
EIA-  Enzyme immuno assay 
ELISA- Enzyme linked immuno sorbent assay 
Ig-  Immunoglobulin 
IUFD- Intrauterine fetal death 
IUGR- Intrauterine growth restriction 
KCT-  Kaolin clotting time 
LAC-  Lupus anticoagulant 
RCOG- Royal College of Obstetricians and Gynaecologists  
RPL-  Recurrent pregnancy 
  
 
 
  
 
PATIENT CONSENT FORM  
  STUDY TITLE:    " SCREENING FOR LUPUS ANTI COAGULANT ANTIBODY AND ANTICARDIOLIPIN ANTIBODY IN RECURRENT 
PREGNANCY LOSS "STUDY CENTRE: Institute of Social Obstetrics& Govt.K.G.H. Chennai-5 
PARTICIPANT NAME:                                         AGE:          SEX:            I.D. NO. 
 
       I confirm that I have understood the purpose of procedure for the above study. I have the opportunity to ask the 
question and all my questions and doubts have been answered to my satisfaction. 
       I have been explained about the possible complications that may occur during the procedure. I understand that my 
participation in the study is voluntary and that I am free to withdraw at any time without giving any reason. 
  
       I understand that investigator, regulatory authorities and the ethics committee will not need my permission to look at my 
health records both in respect to the current study and any further research that may be conducted in relation to it, even if I 
withdraw from the study. I understand that my identity will not be revealed in any information released to third parties of 
published, unless as required under the law. I agree not to restrict the use of any or results that arise from the study. 
       I hereby consent to participate in this study of “ SCREENING FOR LUPUS ANTI COAGULANT ANTIBODY  AND 
ANTICARDIOLIPIN ANTIBODY IN RECURRENT PREGNANCY LOSS " 
 
Signature of Investigator                                                       Place: 
                                                                                              Date: 
Study Investigators Name                                                     Institution: 
Signature / Thumb impression of patient 
                                                                 Thanking you,                       
                                                                                         Yours faithfully, 
                                                                                                                                            
                                                                                                  Postgraduate 
Guide: 
Prof Dr.Abraham Issac ,M.D.,D.G.O , 
Institute of social obstetrics&Govt.KGH, 
Madras Medical College, 
Triplicane, Chennai- 600 005 
  
 
            
